On Mar. 7, 2022, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2 Brilacidin COVID-19 clinical trial results to support Brilacidinﾒs potential inclusion in government-sponsored COVID-19 trials.

Complete analysis of trial results already had begun, with the aim to potentially identify positive trends in the data that could support Brilacidin for inclusion in larger COVID-19 platform trials.